Systems of response evaluation criteria in solid tumors in immunooncology treatment
https://doi.org/10.18027/2224-5057-2017-1-42-46
Abstract
Immunotherapies enhance patients’ endogenous immune system function of attacking tumor cells, and are being widely and successfully used in the field of immuno-oncology. Adoption of assumptions based on more traditional chemotherapy-based responses can lead to significant operational difficulties and inaccurate interpretation of responses seen. It is therefore important to choose the appropriate clinical response criteria. These topics are addressed in this white paper.
About the Authors
D. I. YUDIN
FGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
MD, PhD, senior staff scientist
Russian Federation
MD, PhD, senior staff scientist
K. P. LAKTIONOV
FGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
professor, leading researcher
Russian Federation
professor, leading researcher
K. A. SARANTSEVA
FGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
post-graduate student
Russian Federation
post-graduate student
P. A. CHERNENKO
FGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
MD, PhD, associate scientist
Russian Federation
MD, PhD, associate scientist
A. L. ARZUMANYAN
FGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
MD, PhD, senior staff scientist
Russian Federation
MD, PhD, senior staff scientist
References
1. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207–14.
2. Therasse P., Arbuck S. G. et al.: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 2000 92(3):205–216.
3. Eisenhauer E. A., Therasse P., Bogaerts J. et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). In: Eur. J. Cancer. 45, Nr. 2, Januar 2009, S. 228–47.
4. Laktionov K. K., Sarantseva K. A., Breder V. V. et al. Immunotherapy for non-small cell lung cancer treatment. Malignant Tumours 2016; 3: 18–26.
5. Park J., Kwon M., Shin E. C. Immune checkpoint inhibitors for cancer treatment. Arch Pharm Res. 2016 Nov; 39(11):1577–1587.
6. Sarantseva K. A., Laktionava L. V., Reutova E. V., Chernenko P. A., Breder V. V. Immunology: immune response as leading protectionfactor against cancer. Malignant Tumours 2016; 2: 5–14.
7. Chiou V. L., Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015 Nov 1; 33(31):3541–3.
8. Wolchok J. D., Hoos A., Bohnsack O. et.al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clin Cancer Res 2009; 15(23) December 1, 2009.
9. Nishino M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15; 19(14):3936–43.
10. Nishino M., Gargano M., Suda M., Ramaiya N. H., Hodi F. S. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014; 2: 17. doi:10.1186/2051–1426–2–17.
11. Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, et al. Immune-related response assessment during PD‑1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016; 4: 84.
Review
For citations:
YUDIN D.I., LAKTIONOV K.P., SARANTSEVA K.A., CHERNENKO P.A., ARZUMANYAN A.L. Systems of response evaluation criteria in solid tumors in immunooncology treatment. Malignant tumours. 2017;(1):42-46. (In Russ.) https://doi.org/10.18027/2224-5057-2017-1-42-46
Views:
1681
Email this article 